Impact of Metformin-Induced Gastrointestinal Symptoms on Quality of Life and Adherence in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
AIMS: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). This study assesses the impact of 1) metformin on GI symptoms and health-related quality of life (HRQoL) and 2) metformin-associated GI symptoms on medication adherence in patients with type 2 diabetes newly beginning therapy. METHODS: Patients with T2DM aged>or=18 years starting metformin from January to June 2007 who filled their prescriptions for >or=3 months were identified from a health benefits company database. Via telephone, GI symptom impact was evaluated in a 360-patient sample using the validated Bowel Symptom Questionnaire and Medical Outcomes Study 36-Item Short-Form Health (SF-36) survey. Adherence was assessed using the medication possession ratio (MPR). Logistic regression adjusting for demographic and clinical covariates was used to assess the relationship between GI symptoms and MPR<80%. RESULTS: The most and least common GI symptoms reported were diarrhea (62.1%) and retching (21.1%), respectively. Most GI symptoms were associated with lower physical and mental HRQoL (P<0.05). Most changes in specific HRQoL reached the minimum important difference of 3 points. Bloating, nausea, and abdominal pain were significantly associated with MPR<80%. Adjustment for demographic, clinical, and HRQoL factors made these relationships less evident. CONCLUSIONS: Metformin-associated GI symptoms in patients with T2DM lead to lower physical and mental HRQoL, which may result in patient nonadherence or physician reluctance to optimally titrate the metformin dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · cited 1×
“To reduce the adverse GI symptoms, such as diarrhea, nausea, vomiting, abdominal bloating, abdominal cramping or pain, fl atulence, and anorexia, that occur in approximately 10% to 30% of metformin recipients,(11,12) management guidelines suggest a dose-titration process.(10,13) Despite such a relatively high incidenc…”
BackgroundBytzer, P., Talley, N. J., Leemon, M., Young, L. J., Jones, M. P., & Horowitz, M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.16.1989 · Cited by 632 · cited 1×
“5% of patients without diabetes.(9) In another study, GI symptoms in the past 3 months were reported by 55% of patients with diabetes and 43% of patients without.”
BackgroundImpact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life
Talley, N. J., Young, L., Bytzer, P., Hammer, J., Leemon, M., Jones, M., & Horowitz, M. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03350.x · Cited by 220
Quan, C., Talley, N. J., Jones, M. P., Spies, J., & Horowitz, M. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01943.x · Cited by 55 · cited 1×
“In another study, GI symptoms in the past 3 months were reported by 55% of patients with diabetes and 43% of patients without.(7) Despite the commonality of GI symptoms in patients with T2DM, information on their association with oral medications used for T2DM management and their impact on HRQoL is limited.”
Background
Cited by
Cellular and Molecular Mechanisms of Metformin Action
LaMoia, T. E., & Shulman, G. I. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa023 · Cited by 791
Shippee, N. D., Shah, N. D., May, C. R., Mair, F. S., & Montori, V. M. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.05.005 · Cited by 728
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374
Medication Adherence With Diabetes Medication: A Systematic Review of the Literature
Capoccia, K., Odegard, P. S., & Letassy, N. (2016) · The Diabetes Educator · doi:10.1177/0145721715619038 · Cited by 291
Dujic, T., Zhou, K., Donnelly, L. A., Tavendale, R., Palmer, C. N. A., & Pearson, E. R. (2015) · Diabetes · doi:10.2337/db14-1388 · Cited by 278
Bauer, P. V., Duca, F. A., Waise, T. M. Z., Rasmussen, B. A., Abraham, M. A., Dranse, H. J., Puri, A., O’Brien, C. A., & Lam, T. K. T. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.019 · Cited by 265
Understanding and overcoming metformin gastrointestinal intolerance
Bonnet, F., & Scheen, A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12854 · Cited by 256
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223
Facilitating Healthy Coping in Patients With Diabetes: A Systematic Review
Thorpe, C. T., Fahey, L. E., Johnson, H., Deshpande, M., Thorpe, J. M., & Fisher, E. B. (2013) · The Diabetes Educator · doi:10.1177/0145721712464400 · Cited by 155
The metabolic role of vagal afferent innervation
Waise, T. M. Z., Dranse, H. J., & Lam, T. K. T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0062-1 · Cited by 140
Pharmacological treatment of diabetes in older people
Valencia, W. M., & Florez, H. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12362 · Cited by 62
Self-citation
Metadata
- Authors
- Florez, H., Luo, J., Castillo-Florez, S., Mitsi, G., Hanna, J., Tamariz, L., Palacio, A., Nagendran, S., & Hagan, M.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2010-03
- Volume
- 122
- Issue
- 2
- Pages
- 112-120
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W2044629416
- Cited by
- 112
- References
- 6
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.